University of Michigan

InflaRx has exclusively licencensed the rights for 2 key technology patents of the University of Michigan securing the sepsis indication for blockade of specific complement activation products. Two of the founders of InflaRx are registered inventors on these patents.

Beijing Mabworks Biotech Ltd. Co

InflaRx is actively collaborating with Beijing Mabworks Biotech Co. Ltd for the development and design of new prototype humanized and fully human monoclonal antibodies in a joint contracted business approach, actively managed and supervised by the CSO of InflaRx.